id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10176 R37248 |
Blotière (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Spina bifida | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
5.86 [0.37;93.89] C excluded (control group) |
1/512 1/2,997 | 2 | 512 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9766 R34898 |
Blotière (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2019 | Spina bifida | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 6.00 [0.20;33.50] | 1/512 616/1,875,733 | 617 | 512 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9643 R35006 |
Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Spina bifida | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.22 [0.02;61.38] C excluded (control group) |
0/685 0/833 | 0 | 685 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9646 R34327 |
Veiby (Carbamazepine) (Controls unexposed, sick) (Mixed indications), 2014 | Spina bifida | throughout pregnancy | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 0.79 [0.04;15.25] C | 0/685 3/3,773 | 3 | 685 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9608 R34066 |
Charlton (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2011 | Spina bifida | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
0.31 [0.01;15.93] C excluded (control group) |
0/311 0/98 | 0 | 311 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9609 R34069 |
Charlton (Carbamazepine) (Controls unexposed, sick), 2011 | Spina bifida | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: No | 0.58 [0.03;12.10] C | 0/311 2/902 | 2 | 311 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9648 R34332 |
Viinikainen (Carbamazepine) (Controls unexposed, sick) a, 2006 | Spina bifida | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 0.72 [0.01;36.90] C | 0/72 0/52 | 0 | 72 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9652 R34345 |
Artama (Carbamazepine), 2005 | Spina bifida | 1st trimester | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 1.17 [0.02;58.86] C | 0/805 0/939 | 0 | 805 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9740 R34713 |
Van der Pol (Carbamazepine) (Controls unexposed, disease free), 1991 | Spina bifida occulta | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
5.19 [0.10;276.47] C excluded (control group) |
0/11 0/55 | 0 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9741 R34738 |
Van der Pol (Carbamazepine) (Controls unexposed, sick), 1991 | Spina bifida occulta | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 0.65 [0.02;17.40] C | 0/11 1/22 | 1 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 6 studies | 1.26 [0.34;4.58] | 623 | 2,396 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Controls unexposed NOS) (Mixed indications; 2: Carbamazepine) (Controls unexposed, sick) (Mixed indications; 3: Carbamazepine) (Controls unexposed, sick; 4: Carbamazepine) (Controls unexposed, sick) ; 5: Carbamazepine; 6: Carbamazepine) (Controls unexposed, sick;
Asymetry test p-value = 0.2072 (by Egger's regression)
slope=3.8884 (2.4639); intercept=-2.2893 (1.5230); t=1.5031; p=0.2072
excluded 9740, 9608, 9643, 10176